What is the appropriate use, dosing, contraindications, and monitoring for roflumilast in patients with severe chronic obstructive pulmonary disease (COPD)?

Roflumilast in Severe COPD

Roflumilast should be prescribed at 500 mcg once daily for patients with severe to very severe COPD (FEV1 <50% predicted), chronic bronchitis symptoms, and a history of exacerbations despite optimal inhaled therapy (LAMA/LABA ± ICS). 1

Appropriate Patient Selection

Target Population:

• Post-bronchodilator FEV1/FVC <0.70 AND FEV1 <50% predicted 1
• Chronic bronchitis symptoms (chronic cough and sputum production) 2
• History of ≥1 exacerbation in the previous year requiring systemic corticosteroids and/or antibiotics 2
• Already on optimal inhaled therapy (long-acting bronchodilators ± inhaled corticosteroids) 1

Enhanced Benefit Subgroups:

• Prior hospitalization for COPD exacerbations 3
• Blood eosinophil count ≥300 cells/µL 3
• Patients continuing to exacerbate on triple therapy (LAMA/LABA/ICS) 4

Dosing Regimen

Standard Dosing: 5

• Maintenance dose: 500 mcg once daily (oral)
• Can be taken with or without food

Up-titration Strategy (Recommended to improve tolerability): 5, 6

• Start with 250 mcg once daily for the first 4 weeks
• Then increase to 500 mcg once daily thereafter
• This approach reduces treatment discontinuations by approximately 50% while maintaining efficacy 6

Important: The 250 mcg dose is NOT therapeutic and should only be used as a starting dose for 4 weeks 5

Absolute Contraindications

5

• Moderate to severe hepatic impairment (Child-Pugh B or C)
• This is the only absolute contraindication per FDA labeling

Warnings and Precautions

Psychiatric Events (Most Critical): 5

• Carefully weigh risks versus benefits in patients with history of depression or suicidal ideation
• Advise patients and caregivers to monitor for emergence or worsening of:
  • Insomnia (3.1% vs 1.1% placebo) 1
  • Anxiety and depression (7.1% vs 3.5% placebo) 1
  • Suicidal thoughts
• Contact healthcare provider immediately if mood changes occur

Weight Loss: 5

• Monitor weight regularly
• Weight loss occurs in 8.4% vs 2.3% on placebo 1
• If unexplained or clinically significant weight loss occurs, evaluate and consider discontinuation

Gastrointestinal Effects: 1

• Diarrhea: 4.0% vs 1.0% placebo
• Nausea: 4.8% vs 1.4% placebo
• These are the most common reasons for discontinuation

Not for Acute Bronchospasm: 5

• Roflumilast is NOT a bronchodilator
• Cannot be used for acute symptom relief

Drug Interactions

5

Avoid Concurrent Use:

• Strong CYP450 inducers (rifampicin, phenobarbital, carbamazepine, phenytoin) - will decrease roflumilast levels and reduce efficacy

Use with Caution:

• CYP3A4 inhibitors (erythromycin, ketoconazole) - increase roflumilast exposure
• Dual CYP3A4/CYP1A2 inhibitors (fluvoxamine, enoxacin, cimetidine) - significantly increase exposure
• Weigh risk versus benefit when combining with these agents

Monitoring Parameters

Baseline Assessment:

• Liver function tests (to exclude moderate-severe hepatic impairment)
• Psychiatric history screening
• Baseline weight
• Confirm severe COPD with FEV1 <50% predicted
• Document chronic bronchitis symptoms and exacerbation history

Ongoing Monitoring:

• Weight at each visit (monthly initially, then quarterly)
• Psychiatric symptoms (at each visit, especially first 3 months)
• Exacerbation frequency (primary efficacy endpoint)
• Lung function (FEV1 typically improves 36-80 mL) 2
• Tolerability assessment (GI symptoms, mood changes)

Expected Benefits

1

• Reduces moderate-to-severe exacerbations by approximately 15% (rate ratio 0.85)
• Particularly effective for severe exacerbations requiring hospitalization
• Modest improvement in lung function (40-80 mL increase in FEV1)
• Prolongs time to next exacerbation
• No mortality benefit demonstrated (though studies underpowered for this outcome)

Common Pitfalls to Avoid

1. Do not use as monotherapy - roflumilast is always an add-on to inhaled bronchodilators 1
2. Do not prescribe for mild-moderate COPD - evidence only supports use in severe disease (FEV1 <50%) 1
3. Do not use without chronic bronchitis phenotype - efficacy primarily in patients with cough and sputum 2
4. Do not continue 250 mcg long-term - insufficient PDE4 inhibition for clinical efficacy 6
5. Do not ignore psychiatric screening - this is the most serious safety concern 5

Special Populations

Nursing Mothers: 5

• Should NOT be used - excretion into breast milk is probable

Elderly: No dose adjustment needed, but monitor closely for adverse effects

Renal Impairment: No dose adjustment required

Position in Treatment Algorithm

Per GOLD 2018 guidelines 7:

• Consider roflumilast in Group D patients (high symptoms, frequent exacerbations) with FEV1 <50% and chronic bronchitis who continue to exacerbate despite LAMA/LABA or triple therapy
• Alternative to macrolide therapy in appropriate patients
• Can be combined with triple inhaled therapy (LAMA/LABA/ICS) 4

The 2017 ERS/ATS guideline provides a conditional recommendation with moderate quality evidence for roflumilast use in this specific population, emphasizing that the recommendation values exacerbation prevention over the burden of adverse effects 1.